

Resource Summary Report

Generated by [dkNET](#) on Aug 26, 2026

Human Biological Data Interchange

RRID:SCR_004591

Type: Tool

Proper Citation

Human Biological Data Interchange (RRID:SCR_004591)

Resource Information

URL: http://www.ndriresource.org/NDRI_Initiatives/HBDI/36/

Proper Citation: Human Biological Data Interchange (RRID:SCR_004591)

Description: Database of medical history and genealogical data on over 6700 families who are affected by type 1 diabetes and a repository of DNA and immortalized cell lines collected from 500 families. This database and repository was originally created to help researchers uncover the genetic causes of type 1 diabetes but today, it is also used by researchers who study type 2 diabetes, diabetic complications, autoimmune diseases, kidney disease, and other disorders. The following resources and services are available to researchers through HBDI: * International Type 1 Diabetes Database: This database includes more than 6700 families with diabetes, related complications and other genetic diseases. There are extensive genealogical and medical histories for more than 90,000 individuals. NDRI conducts searches of the database for approved research requests. * HBDI Catalog: The catalog contains 503 family pedigrees with associated cell lines, DNA, and serum for research. Also available are HLA-typing and auto-antibody test results for diabetes families in the catalog. * HBDI Repository: The HBDI repository contains cell lines, DNA, and HLA typing information from 480 families, and frozen buffy coats from 23 families, all with Type 1 diabetes. They have recently expanded the repository to include specimens from individuals with rare diseases. * Customized Collections: NDRI will collect data from patients and physicians, conduct phone interviews and collect blood and other specimens for research on request., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Abbreviations: HBDI

Synonyms: Human Biological Data Interchange (HBDI)

Resource Type: biospecimen repository, material storage repository, service resource, storage service resource

Keywords: genetics, medical history, genealogical data, type 2 diabetes, diabetic complication, autoimmune disease, kidney disease, disorder, family pedigree, hla typing,

frozen, buffy coat, catalog, demographic data, clinical data, autoantibody data, FASEB list

Related Condition: Type 1 diabetes, Rare disease, Type 2 diabetes, Diabetic complication, Autoimmune disease, Kidney disease, Diabetes

Funding: NIDDK

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Human Biological Data Interchange

Resource ID: SCR_004591

Alternate IDs: nlx_143829

Record Creation Time: 20220129T080225+0000

Record Last Update: 20260821T193726+0000

Ratings and Alerts

No rating or validation information has been found for Human Biological Data Interchange .

No alerts have been found for Human Biological Data Interchange .

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 107 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sundell J, et al. (2025) Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval. CPT: pharmacometrics & systems pharmacology, 14(2), 292.

Chatzilamprinos K, et al. (2024) Evaluation of Strength and Functional Ability of Soccer Players Two Years After Anterior Cruciate Ligament Reconstruction: A Cross-sectional Study. Journal of musculoskeletal & neuronal interactions, 24(1), 55.

Parkinson J, et al. (2024) The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology research & perspectives, 12(2), e1184.

Ram S, et al. (2024) Quantitative performance assessment of Ultivue multiplex panels in formalin-fixed, paraffin-embedded human and murine tumor specimens. Scientific reports, 14(1), 8496.

Kang EJ, et al. (2024) A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17). *ESMO open*, 9(9), 103668.

Sunnåker M, et al. (2024) Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers. *Clinical drug investigation*, 44(11), 863.

Talbot EJ, et al. (2024) cGAS-STING signalling regulates microglial chemotaxis in genome instability. *Nucleic acids research*, 52(3), 1188.

Reinig S, et al. (2024) Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines. *medRxiv : the preprint server for health sciences*.

Hardaker EL, et al. (2024) The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. *Nature communications*, 15(1), 1700.

Besse B, et al. (2024) Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. *Nature medicine*, 30(3), 716.

Tay T, et al. (2024) Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay. *Cell reports. Medicine*, 5(11), 101804.

Karapetyan L, et al. (2024) Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. *Journal for immunotherapy of cancer*, 12(11).

Yang X, et al. (2023) Multiple primary melanoma in association with other personal and familial cancers. *Cancer medicine*, 12(3), 2474.

Rodríguez-Garza NE, et al. (2023) In Vitro Biological Activity and Lymphoma Cell Growth Inhibition by Selected Mexican Medicinal Plants. *Life (Basel, Switzerland)*, 13(4).

Wildsmith S, et al. (2023) Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(11), 2066.

Ptasinski V, et al. (2023) Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids. *Life science alliance*, 6(8).

Ashby J, et al. (2023) The Reliability and Validity of a Portable Three-Dimensional Scanning System to Measure Leg Volume. *Sensors (Basel, Switzerland)*, 23(22).

Aggarwal C, et al. (2023) Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(3), 560.

Amoakoh-Coleman M, et al. (2023) Ethical considerations for biobanking and use of genomics data in Africa: a narrative review. BMC medical ethics, 24(1), 108.

Lee DH, et al. (2023) Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma. Cancer medicine, 12(15), 16066.